Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose. Authors' reply

Aliment Pharmacol Ther. 2022 Jun;55(11):1457-1458. doi: 10.1111/apt.16932.

Carlos K H Wong^{1

2

3}, Ivan C H Au¹, Wing Yiu Cheng⁴, Kenneth K C Man^{1

5}, Kristy T K Lau¹, Lung Yi Mak^{6

7}, Sing Leung Lui⁸, Matthew S H Chung¹, Xi Xiong¹, Eric H Y Lau^{3

9}, Benjamin J Cowling^{3

9}

¹ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
² Department of Family Medicine and Primary Care, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
³ Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.
⁴ School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
⁵ Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
⁶ Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
⁷ State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, China.
⁸ Department of Medicine, Tung Wah Hospital, Hong Kong SAR, China.
⁹ WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, Hong Kong SAR, China.

No abstract available

Publication types